

EAGLE PHARMACEUTICALS, INC.
Form 8-K
March 17, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 17, 2015**

Eagle Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36306
(Commission File Number)

20-8179278
(IRS Employer Identification No.)

50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ
(Address of principal executive offices)

07677
(Zip Code)

Registrant's telephone number, including area code: **(201) 326-5300**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 8-K

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 8-K

Exhibit No.	Description
1.1	Underwriting Agreement, dated March 17, 2015, by and among Eagle Pharmaceuticals, Inc., and Piper Jaffray & Co. and William Blair & Company, L.L.C., as representatives of the several underwriters listed in Schedule II thereto, and the Selling Stockholders named in Schedule I thereto.
5.1	Opinion of Cooley LLP
23.1	Consent of Cooley LLP (included as part of Exhibit 5.1)
99.1	Press Release of Eagle Pharmaceuticals, Inc. dated March 17, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Eagle Pharmaceuticals, Inc.

Dated: March 17, 2015

By: /s/ Scott Tarriff
Scott Tarriff
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
1.1	Underwriting Agreement, dated March 17, 2015, by and among Eagle Pharmaceuticals, Inc., and Piper Jaffray & Co. and William Blair & Company, L.L.C., as representatives of the several underwriters listed in Schedule II thereto, and the Selling Stockholders named in Schedule I thereto
5.1	Opinion of Cooley LLP
23.1	Consent of Cooley LLP (included as part of Exhibit 5.1)
99.1	Press Release of Eagle Pharmaceuticals, Inc. dated March 17, 2015